SAGE - Sage Therapeutics Inc. (SAGE) Q1 2024 Earnings Call Transcript

2024-04-25 14:17:02 ET

Sage Therapeutics, Inc. (SAGE)

Q1 2024 Earnings Conference Call

April 25, 2024 08:00 AM ET

Company Participants

Ashley Kaplowitz - Vice President-Investor Relations & Capital Markets

Barry Greene - Chief Executive Officer & Member-Board of Directors

Chris Benecchi - Chief Business Officer

Laura Gault - Chief Medical Officer

Kimi Iguchi - Chief Financial Officer

Mike Quirk - Chief Scientific Officer

Conference Call Participants

Anupam Rama - JPMorgan

Ritu Baral - TD Cowen

Laura Chico - Wedbush Securities

Paul Matteis - Stifel

Jay Olson - Oppenheimer

Ami Fadia - Needham

Brian Abrahams - RBC Capital Markets

George Farmer - Scotiabank

Sumant Kulkarni - Canaccord

Yatin Suneja - Guggenheim

Douglas Tsao - HC Wainwright

Presentation

Operator

Good morning, and welcome to Sage Therapeutics First Quarter 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Sage's website at sagerx.com. This call is the property of Sage Therapeutics and recording, reproduction, or transmission of this call without the expressed written consent of Sage Therapeutics is strictly prohibited. Please note that this call is being recorded.

I would now like to introduce Ashley Kaplowitz, Vice President of Investor Relations and Capital Markets at Sage.

Ashley Kaplowitz

Good morning, and thank you for joining Sage Therapeutics' first quarter 2024 financial results conference call. Before we begin, I encourage everyone to go to the Investors & Media section of our website at sagerx.com, where you can find the press release and slides related to today's call.

I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please review the risk factors discussed in today's press release and in our SEC filings for additional details.

We will begin the call with prepared remarks by Barry Greene, our Chief Executive Officer, who will provide an overview of our progress during the first quarter of 2024. Our Chief Business Officer, Chris Benecchi will provide an update on the ongoing commercialization of ZURZUVAE. We will also be joined by Laura Gault, our Chief Medical Officer; who will review development activities across our programs.

We will then be joined by Kimi Iguchi, our Chief Financial Officer, who will review our financial results from the first quarter of 2024. Mike Quirk, our Chief Scientific Officer will be available for questions during the Q&A portion of the call.

With that, I'll now turn the call over to Barry.

Barry Greene

Thanks, Ashley, and thank you everyone for joining us this morning. As we progress through 2024, we are singularly focused on addressing unmet needs in brain health. And while the science is extremely challenging, we remain motivated toward a common goal improving human health.

As you may have seen last week we announced negative results from our PRECEDENT study in the dalzanemdor program and participants with mild cognitive impairment related to Parkinson's disease....

For further details see: